NYSE
NYSE
(ABT) Stock Forecast and AI Recommendations
Abbott Laboratories (ABT) Stock Stock Prediciton and Price Targets
ABT sees MACD Histogram just turned negative
ABT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 04, 2022. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 21 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 42%.
Current price $128.12 is below $133.78 the lowest support line found by A.I. Throughout the month of 12/14/21 - 01/14/22, the price experienced a -3% Downtrend. During the week of 01/07/22 - 01/14/22, the stock fell -5%.
The Momentum Indicator moved below the 0 level on January 05, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on ABT as a result. In 28 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 34%.
ABT moved below its 50-day Moving Average on January 13, 2022 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 38%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 206 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
ABT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 199 of 364 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.583) is normal, around the industry mean (9.351). P/E Ratio (31.847) is within average values for comparable stocks, (71.773). Projected Growth (PEG Ratio) (2.500) is also within normal values, averaging (4.280). Dividend Yield (0.014) settles around the average of (0.017) among similar stocks. P/S Ratio (5.426) is also within normal values, averaging (118.646).
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
ABT is expected to report earnings to fall 14.29% to $1.20 per share on January 26
Headlines
General Information
| Industry | Medical Specialties |
| Address | 100 Abbott Park Road, Abbott Park, IL, 60064-6400 |
| Phone | +1 224 667-6100 |
| Employees | 107000 |
| Web | https://www.abbott.com |
Select Stock attributes to show
|
|
227B |
|
|
31.85 |
|
|
0.69 |
|
|
0.01 |
|
|
8.944B |
|
|
5.06 |
|
|
18.5B |
|
|
33.06 |
|
|
2.50 |
|
|
24% |
|
|
40.2B |
|
|
N/A |
|
|
33.8B |
|
|
6.58 |
|
|
N/A |
|
|
3.570 |
|
|
N/A |
|
|
24.2B |
|
|
1.79 |
|
|
93,788.99 |
|
|
0.45 |
|
|
11.2B |
|
|
N/A |
|
|
N/A |
|
|
51.61 |
|
|
8.98 |
|
|
1.323T |
|
|
N/A |
|
|
39.2B |
|
|
N/A |
| Value | Over |
| Gain YTD | -8.617 |
| Group | Domestic Stock Funds |
| Category | Medical Specialties |
|
|
|
|
|
0.00 USD |
|
|
|
|
|
|
|
|
|
|
|
0.00 USD |
|
|
| Group | Domestic Stock Funds | |
| Category | Medical Specialties | |
|
|
226.62b USD | |
|
|
31.847134 | |
|
|
8.94b USD | |
|
|
2.50 | |
|
|
18.50b USD | |
|
|
40.23b USD | |
|
|
0.69 | |
|
|
0.01 | |
|
|
5.06 | |
|
|
33.06 | |
|
|
24.00USD | as % of share price |
| Group | Domestic Stock Funds |
| Category | Medical Specialties |
|
|
0.00 USD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Group | Domestic Stock Funds |
| Category | Medical Specialties |
| Market Capitalization | 0.00 USD |
| Volume | 0.00 USD |